Healthcare / BiotechnologyKOSDAQ
$42500.00
+1700.00 (+4.17%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 20%
FCF escenarios
weak_data · normalized FCF $-1.9B · quality 53.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
35/100
D
Piotroski
6/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$345.4B
P/E
N/A
•EV/EBITDA
607.0x
↑ROE
-0.6%
↓Gross Margin
70.0%
↑Debt/Equity
0.16
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+80.6%
FCF CAGR
—
FCF margin
-11.5%
FCF / Net income
6.11x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $16.48B · net income $-311.1M · FCF $-1.90B
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $16.48B | $16.48B | $9.54B | $4.88B | $2.80B |
| Net Income | $-311.1M | $-311.1M | $2.86B | $-7.52B | $-5.73B |
| EBITDA | $574.7M | $574.7M | $3.87B | $-6.48B | $-4.91B |
| EPS | -38.00 | -38.00 | -262.00 | -1198.00 | -923.00 |
| Gross Margin | 70.0% | 70.0% | 61.0% | 43.2% | 10.2% |
| Operating Margin | -4.4% | -4.4% | -37.5% | -107.1% | -206.4% |
| Net Margin | -1.9% | -1.9% | 30.0% | -154.1% | -205.1% |
| Balance Sheet | |||||
| Debt/Equity | 0.16 | 0.16 | 0.24 | -1.95 | -43.40 |
| Current Ratio | 5.11 | 5.11 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-1.90B | $-1.90B | $-1.64B | $-4.22B | $-8.40B |
| Returns | |||||
| ROE | -0.6% | -0.6% | 6.3% | 127.5% | 2258.0% |
| Valuation | |||||
| EV/EBITDA | 606.98 | 606.98 | 87.97 | — | — |
| P/B | 7.23 | 7.23 | 7.40 | — | — |
| Growth & Yield | |||||
| Revenue Growth | 72.7% | 72.7% | 95.5% | 74.7% | — |
| EPS Growth | 85.5% | 85.5% | 78.1% | -29.8% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+8.1%
Start / end P/E
n/dx → n/dx
EPS bridge
-262.00 → -38.00
Residual
+8.1%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.